DE602005017131D1 - Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose - Google Patents

Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose

Info

Publication number
DE602005017131D1
DE602005017131D1 DE602005017131T DE602005017131T DE602005017131D1 DE 602005017131 D1 DE602005017131 D1 DE 602005017131D1 DE 602005017131 T DE602005017131 T DE 602005017131T DE 602005017131 T DE602005017131 T DE 602005017131T DE 602005017131 D1 DE602005017131 D1 DE 602005017131D1
Authority
DE
Germany
Prior art keywords
adefovir
tenofovir
breast cancer
viruses
connection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005017131T
Other languages
German (de)
English (en)
Inventor
Tomas Cihlar
Janet L Douglas
Craig S Gibbs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of DE602005017131D1 publication Critical patent/DE602005017131D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE602005017131T 2004-01-21 2005-01-21 Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose Expired - Lifetime DE602005017131D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53806604P 2004-01-21 2004-01-21
PCT/US2005/002043 WO2005072748A1 (en) 2004-01-21 2005-01-21 Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis

Publications (1)

Publication Number Publication Date
DE602005017131D1 true DE602005017131D1 (de) 2009-11-26

Family

ID=34825960

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005017131T Expired - Lifetime DE602005017131D1 (de) 2004-01-21 2005-01-21 Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose

Country Status (10)

Country Link
US (2) US20070281911A1 (cg-RX-API-DMAC7.html)
EP (1) EP1732569B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007518815A (cg-RX-API-DMAC7.html)
AT (1) ATE445404T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005209256B2 (cg-RX-API-DMAC7.html)
CA (1) CA2553455A1 (cg-RX-API-DMAC7.html)
DE (1) DE602005017131D1 (cg-RX-API-DMAC7.html)
ES (1) ES2334149T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ548532A (cg-RX-API-DMAC7.html)
WO (1) WO2005072748A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1879657A2 (en) * 2005-04-25 2008-01-23 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of compounds to enhance processivity of telomerase
RU2301088C2 (ru) * 2005-09-01 2007-06-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения рецидива рака молочной железы
ATE534377T1 (de) 2006-05-16 2011-12-15 Gilead Sciences Inc Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen
ES2566762T3 (es) * 2009-10-05 2016-04-15 Ambergen Inc. Un procedimiento de diagnóstico de cirrosis biliar primaria (PBC) usando nuevos autoantígenos
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
EP3161159B1 (en) 2014-06-25 2020-08-05 The General Hospital Corporation Targeting human satellite ii (hsatii)
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
GB201509431D0 (en) * 2015-06-01 2015-07-15 Equigerminal Sa Antiviral composition
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
KR102196711B1 (ko) * 2018-08-30 2020-12-30 가톨릭대학교 산학협력단 테노포비르 디소프록실 푸마르산을 유효성분으로 함유하는, 간섬유증 예방 또는 치료용 약학적 조성물
WO2020171225A1 (ja) * 2019-02-22 2020-08-27 一素 村田 mTOR阻害剤
US12029783B2 (en) 2019-07-02 2024-07-09 Virago Vax Inc. Mammary tumor virus vaccine
US12016844B2 (en) 2019-07-02 2024-06-25 Virago Vax Inc. Mammary tumor virus suppression
EP3993873A4 (en) * 2019-07-02 2023-09-20 Virago Vax Inc. SUPPRESSION OF BREAST TUMORS
CN119546620A (zh) 2022-03-15 2025-02-28 罗梅治疗股份有限公司 用于治疗疾病的化合物和方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073507A2 (en) * 1999-06-01 2000-12-07 Alton Ochsner Medical Foundation Identification of a novel retrovirus associated with primary biliary cirrhosis and autoimmune disorders
ATE399204T1 (de) * 1999-06-30 2008-07-15 Univ Tulane Humanes endogenes retrovirus
HRP20030047B1 (hr) * 2000-07-21 2016-02-26 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
IL164809A0 (en) * 2002-05-13 2005-12-18 Metabasis Therapeutics Inc Novel phosphonic acid basdrugs of pmea and its analogues

Also Published As

Publication number Publication date
ATE445404T1 (de) 2009-10-15
CA2553455A1 (en) 2005-08-11
EP1732569B1 (en) 2009-10-14
US20050239753A1 (en) 2005-10-27
HK1099228A1 (en) 2007-08-10
AU2005209256B2 (en) 2010-11-18
AU2005209256A1 (en) 2005-08-11
EP1732569A1 (en) 2006-12-20
JP2007518815A (ja) 2007-07-12
ES2334149T3 (es) 2010-03-05
WO2005072748A1 (en) 2005-08-11
US20070281911A1 (en) 2007-12-06
NZ548532A (en) 2009-09-25

Similar Documents

Publication Publication Date Title
ATE445404T1 (de) Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
BR112023000205A2 (pt) Misturas fungicidas
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
IS7997A (is) Granisetron lyfjaplástur
MX2018009496A (es) Degradadores selectivos del receptor de estrogeno y sus usos.
DK1866324T3 (da) Phosphoramidatderivater af nukleosidforbindelser til anvendelse i behandlingen af cancer
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
BRPI0515319A (pt) análogos de quinolona
CY1108399T1 (el) Τετραϋδροπυριδοθειοφαινια
PH12019550069A1 (en) Nucleoside phosphate compound and preparation method and use thereof
CY1109440T1 (el) Φωσφοϊνδολες ως αναστολεις hiv
ATE541848T1 (de) Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv
IN2012DN03844A (cg-RX-API-DMAC7.html)
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
UY29417A1 (es) Agentes endoparasiticidas
DK1893213T3 (da) Kombination af pyrimidylaminobenzamidforbindelser og imatinib til behandling eller forebyggelse af proliferative sygdomme
ECSP077378A (es) Isoxazoles sustituidos como fungicidas
RU2010139486A (ru) Способ коррекции гиперэстрадиолемии и нормогонадотропного гипогонадизма у мужчин
MX2021006313A (es) Sustancia para el tratamiento y/o prevencion de enfermedades alergicas, y metodo de dise?o y metodo de preparacion de la misma.
UY28563A1 (es) Complejos metálicos de paladio y platino con tiosemicarbazonas derivadas de 5-nitrofurano, procedimiento de preparación y utilización
UA89625C2 (ru) Фосфонаты, монофосфонамидаты, бисфосфонамидаты для лечения вирусных заболеваний
TR200805408U (tr) Kendi̇nden kapsüllü taşima kulbu

Legal Events

Date Code Title Description
8364 No opposition during term of opposition